Cosmos Health Inks Greek Deal for Diabetes Drug DIABIT-IS X
Event summary
- Cosmos Health partners with Libytec to commercialize DIABIT-IS X (sitagliptin) in Greece, a generic alternative to Merck's Januvia®.
- Five-year agreement positions Cosmos in the European sitagliptin market, expected to contribute to revenue and cash-flow visibility.
- DIABIT-IS X will be accessible through Greece’s national health insurance system, broadening its reach.
- Merck’s Januvia® and Janumet® generated $4.5 billion in combined global sales in 2022.
The big picture
This partnership aligns with Cosmos Health’s strategy of expanding its prescription medicine portfolio, particularly in established therapeutic categories. The deal underscores a broader trend of pharmaceutical companies seeking regional partnerships to strengthen distribution and penetration in key markets. With DIABIT-IS X targeting type-2 diabetes—a growing global health concern—Cosmos is positioning itself in a lucrative segment where generic alternatives can capture significant market share.
What we're watching
- Market Expansion
- Whether Cosmos can leverage this deal to enter additional European markets beyond Greece.
- Revenue Impact
- The pace at which DIABIT-IS X contributes meaningfully to Cosmos’ revenue and cash flow.
- Competitive Positioning
- How this move affects Cosmos' standing against larger players like Merck in the sitagliptin market.
Related topics